
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k061005
B. Purpose for Submission:
New product
C. Measurand:
Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Marijuana, Morphine,
Methamphetamine, Methadone, Phencyclidine, and Nortriptyline
D. Type of Test:
Qualitative lateral flow immunochromatographic test
E. Applicant:
Applied DNA Technologies Inc.
F. Proprietary and Established Names:
ACCUSTEP Single and Multi-Strip Cassette/Dipstick DOA Screen Panels
G. Regulatory Information:
1. Regulation section:
21 CFR §862.3100: Test System, Amphetamine
21 CFR §862.3150: Test System, Barbiturate
21 CFR §862.3170: Enzyme Immunoassay, Benzodiazepine
21 CFR §862.3250: Enzyme Immunoassay, Cocaine and Cocaine Metabolites
21 CFR §862.3870: Enzyme Immunoassay, Cannabinoids
21 CFR §862.3640: Morphine test system
21 CFR §862.3610: Test System, Methamphetamine
21 CFR §862.3620: Methadone test system
21 CFR §862.3100: Test System, Amphetamine (Phencyclidine)
21 CFR §862.3910: Tricyclic Antidepressant Drugs Test System
2. Classification:
Class II
3. Product code:
DKZ, DIS, JXM, DIO, LDJ, DNK, DJC, DJR, LCM, LFG
4. Panel:
Toxicology (91)
H. Intended Use:
1. Intended use(s):
See Indications for Use.
1

--- Page 2 ---
2. Indication(s) for use:
The Applied DNA Technologies ACCUSTEP DOA Panels are rapid
chromatographic immunoassays for the qualitative and simultaneous detection of
one to ten of the following drugs in a variety of combinations in human urine. The
designed cutoff concentrations and direct calibrator for these drugs are as follows:
Analyte Abbreviation Calibrator Cutoff Concentration
Amphetamine AMP Amphetamine 1000 ng/ml
Barbiturate BAR Secobarbital 300 ng/ml
Benzodiazepines BZO Benzodiazepine 300 ng/ml
Cocaine COC Benzoylecgonine 300 ng/ml
Marijuana THC 11-nor-Δ9-THC9-COOH 50 ng/ml
Methamphetamine MET Methamphetamine 1000 ng/ml
Methadone MTD Methadone 300 ng/ml
Morphine MOR Morphine 2000 ng/ml
Phencyclidine PCP Phencyclidine 25 ng/ml
Nortriptyline NOR Nortriptyline 1000 ng/ml
These test kits are intended for health care professional use only.
This assay provided only a preliminary analytical test result. A more specific
alternative chemical method must be used in order to obtain a confirmed
analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liquid
Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory
method.
Clinical consideration and professional judgment should be applied to any drug of
abuse test result, particularly when preliminary positive results are indicated.
3. Special conditions for use statement(s):
For professional prescription use only.
This assay provides only a preliminary analytical test result. A more specific
alternative chemical method must be used in order to obtain a confirmed
analytical result. GC/MS or LC/MS are the preferred confirmatory methods.
4. Special instrument requirements:
Not applicable, as the devices are visually-read single-use devices.
I. Device Description:
The ACCUSTEP DOA test has two formats: cassette and dipstick. These two formats
are manufactured with the same formulation, components, and manufacturing
processes. The Cassette contains a testing in a plastic housing with a specimen well
and a window to read the test results. A specimen pipette is included with the Test
Device, but a specimen collection container is not included with either test format.
2

--- Page 3 ---
J. Substantial Equivalence Information:
1. Predicate device name(s):
ACON One Step Multi-Drug Multi-Line Screen Test Card/Device
2. Predicate 510(k) number(s):
k020313, k023946
3. Comparison with predicate:
The device is similar to or the same as to the previously cleared predicate(s) in the
following ways: test principles, indication for use, cut-off concentration(s), use in
a professional setting, sample matrix, endpoint, and test time.
The devices differ by manufacturer, specific monoclonal antibodies used, and the
proposed device is not cleared for use in point-of-care settings.
K. Standard/Guidance Document Referenced (if applicable):
None referenced by the manufacturer.
L. Test Principle:
The devices employ lateral flow immunochromatographic technology and are based
on the principle of competitive binding. Drug, if present in concentrations below the
cutoff level, will not saturate the binding sites of antibody-coated particles in the
device. The antibody-coated particles will then be captured by immobilized drug-
specific conjugate and a colored line will appear in the test line region. A line will
not form if the sample contains drug in excess of the cutoff level because the drug
will saturate all the binding sites of the drug-specific antibody. Each strip in the
device contains a procedural control. Formation of a line in the control line region
indicates that the proper volume of urine has been added and membrane wicking has
occurred. If a line does not form in the control region then the test is not valid and
users are cautioned to repeat the test. A ‘presumptive positive’ is determined by the
appearance of a procedural control line AND no line appearing next to the test region.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Drug-free urine was spiked with drug to concentrations of 50%, 75%, 125%,
150%, and 300% of the cutoff; test strips from one lot and cassettes from one
lot were tested in duplicate for 15 or 19 days respectively (n = 30 or 38 per
format; 60 or 76 total). Results were read by three observers after five minutes
as ‘positive’ or as ‘negative’. There was no significant difference in precision
between the two lots or between the readers:
3

--- Page 4 ---
Drug/Test Conc % Correct by Reader Drug/Test Conc % Correct by Reader
AMP (n = 60) 1 2 3 MOR (n = 60) 1 2 3
Negative 100 100 100 Negative 100 100 100
50% c/o 100 100 100 50% c/o 100 100 100
75% c/o 83 83 82 75% c/o 87 88 88
125% c/o 83 83 83 125% c/o 88 92 97
150% c/o 100 100 100 150% c/o 100 100 100
300% c/o 100 100 100 300% c/o 100 100 100
BAR (n = 60) 1 2 3 MTD (n = 76) 1 2 3
Negative 100 100 100 Negative 100 100 100
50% c/o 100 100 100 50% c/o 100 100 100
75% c/o 88 88 87 75% c/o 100 100 100
125% c/o 82 80 82 125% c/o 100 100 99
150% c/o 100 100 100 150% c/o 100 100 100
300% c/o 100 100 100 300% c/o 100 100 100
BZO (n = 60) 1 2 3 PCP (n = 76) 1 2 3
Negative 100 100 100 Negative 100 100 100
50% c/o 100 100 100 50% c/o 100 100 100
75% c/o 85 87 85 75% c/o 100 100 100
125% c/o 83 83 85 125% c/o 100 100 100
150% c/o 100 100 100 150% c/o 100 100 100
300% c/o 100 100 100 300% c/o 100 100 100
COC (n = 76) 1 2 3 NOR (n = 60) 1 2 3
Negative 100 100 100 Negative 100 100 100
50% c/o 100 100 100 50% c/o 100 100 100
75% c/o 100 100 100 75% c/o 88 88 85
125% c/o 100 100 100 125% c/o 85 85 85
150% c/o 100 100 100 150% c/o 100 100 100
300% c/o 100 100 100 300% c/o 100 100 100
MET (n = 76) 1 2 3 THC (n = 60) 1 2 3
Negative 100 100 100 Negative 100 100 100
50% c/o 100 100 100 50% c/o 100 100 100
75% c/o 99 100 97 75% c/o 85 85 85
125% c/o 100 100 100 125% c/o 87 83 87
150% c/o 100 100 100 150% c/o 100 100 100
300% c/o 100 100 100 300% c/o 100 100 100
b. Linearity/assay reportable range:
Not applicable. The assay is intended for qualitative use.
4

[Table 1 on page 4]
Drug/Test Conc	% Correct by Reader					Drug/Test Conc	% Correct by Reader		
AMP (n = 60)	1	2	3			MOR (n = 60)	1	2	3
Negative	100	100	100			Negative	100	100	100
50% c/o	100	100	100			50% c/o	100	100	100
75% c/o	83	83	82			75% c/o	87	88	88
125% c/o	83	83	83			125% c/o	88	92	97
150% c/o	100	100	100			150% c/o	100	100	100
300% c/o	100	100	100			300% c/o	100	100	100
									
BAR (n = 60)	1	2	3			MTD (n = 76)	1	2	3
Negative	100	100	100			Negative	100	100	100
50% c/o	100	100	100			50% c/o	100	100	100
75% c/o	88	88	87			75% c/o	100	100	100
125% c/o	82	80	82			125% c/o	100	100	99
150% c/o	100	100	100			150% c/o	100	100	100
300% c/o	100	100	100			300% c/o	100	100	100
									
									
BZO (n = 60)	1	2	3			PCP (n = 76)	1	2	3
Negative	100	100	100			Negative	100	100	100
50% c/o	100	100	100			50% c/o	100	100	100
75% c/o	85	87	85			75% c/o	100	100	100
125% c/o	83	83	85			125% c/o	100	100	100
150% c/o	100	100	100			150% c/o	100	100	100
300% c/o	100	100	100			300% c/o	100	100	100
									
COC (n = 76)	1	2	3			NOR (n = 60)	1	2	3
Negative	100	100	100			Negative	100	100	100
50% c/o	100	100	100			50% c/o	100	100	100
75% c/o	100	100	100			75% c/o	88	88	85
125% c/o	100	100	100			125% c/o	85	85	85
150% c/o	100	100	100			150% c/o	100	100	100
300% c/o	100	100	100			300% c/o	100	100	100
									
MET (n = 76)	1	2	3			THC (n = 60)	1	2	3
Negative	100	100	100			Negative	100	100	100
50% c/o	100	100	100			50% c/o	100	100	100
75% c/o	99	100	97			75% c/o	85	85	85
125% c/o	100	100	100			125% c/o	87	83	87
150% c/o	100	100	100			150% c/o	100	100	100
300% c/o	100	100	100			300% c/o	100	100	100
									

--- Page 5 ---
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
This device has internal process controls. A red line appearing in the control
region confirms sufficient sample volume and adequate membrane wicking.
Users are informed not to interpret the test if no line forms in the control
region.
Control standards are not supplied with this device; however it is good
laboratory practice to confirm the test procedure and to verify proper test
performance. Users should follow all applicable guidelines for testing QC
materials.
d. Detection limit:
To test the analytical sensitivity of the devices, drug-free urine was spiked
with drug to concentrations of 50%, 75%, 125%, 150%, and 300% of the
cutoff; 25 test strips from one lot and 25 cassettes from one lot were tested.
Drug concentrations were confirmed by GC/MS:
Amphetamine Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 7 18 72 9 16 64
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Barbiturates Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 5 20 80 6 19 76
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Benzodiazepines Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
5

[Table 1 on page 5]
Amphetamine		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	7	18	72	9	16	64
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 2 on page 5]
Barbiturates		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	5	20	80	6	19	76
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 3 on page 5]
Benzodiazepines		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100

--- Page 6 ---
Benzodiazepines Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
750 75% 25 0 100 25 0 100
1000 Cutoff 9 16 64 8 17 68
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Cocaine Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 5 20 80 6 19 76
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Marijuana (THC) Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 10 15 60 7 18 72
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Methadone Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 2 23 92 4 21 84
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
6

[Table 1 on page 6]
Benzodiazepines		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
750	75%	25	0	100	25	0	100
1000	Cutoff	9	16	64	8	17	68
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 2 on page 6]
Cocaine		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	5	20	80	6	19	76
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 3 on page 6]
Marijuana (THC)		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	10	15	60	7	18	72
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 4 on page 6]
Methadone		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	2	23	92	4	21	84
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

--- Page 7 ---
Methamphetamine Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 11 14 56 12 13 52
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Morphine Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 7 18 72 6 19 76
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Phencyclidine Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 4 21 84 5 20 80
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
Nortriptyline Strip Cassette
Conc % of Reading % Reading %
(ng/mL) Cutoff Neg Pos Correct Neg Pos Correct
0 0 25 0 100 25 0 100
500 50% 25 0 100 25 0 100
750 75% 25 0 100 25 0 100
1000 Cutoff 4 21 84 5 20 80
1250 125% 0 25 100 0 25 100
1500 150% 0 25 100 0 25 100
3000 300 % 0 25 100 0 25 100
7

[Table 1 on page 7]
Methamphetamine		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	11	14	56	12	13	52
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 2 on page 7]
Morphine		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	7	18	72	6	19	76
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 3 on page 7]
Phencyclidine		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	4	21	84	5	20	80
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

[Table 4 on page 7]
Nortriptyline		Strip			Cassette		
Conc
(ng/mL)	% of
Cutoff	Reading		%
Correct	Reading		%
Correct
		Neg	Pos		Neg	Pos	
0	0	25	0	100	25	0	100
500	50%	25	0	100	25	0	100
750	75%	25	0	100	25	0	100
1000	Cutoff	4	21	84	5	20	80
1250	125%	0	25	100	0	25	100
1500	150%	0	25	100	0	25	100
3000	300 %	0	25	100	0	25	100

--- Page 8 ---
e. Analytical specificity:
The drugs tested for by these devices, their known metabolites, and related
compounds were spiked into drug-free urine then serially diluted and tested
until the concentrations which yielded a negative result were obtained. The
following tables list the lowest concentration (ng/mL) which yields a positive
result for the compound being tested.
ACCUSTEP DOA Tests: Cross Reactivity of Compounds
Amphetamine - related Conc Methamphetamine - related
Conc
compounds compounds
d-Amphetamine 1000 d-Methamphetamine 1000
l-Amphetamine >50,000 d-Amphetamine >40,000
d-Methamphetamine >20,000 Chloroquine 10,000
l-Methamphetamine >20,000 (+/-) Ephedrine >100,000
3,4-Methylenediioxyamphetamine
2,400 l-Methamphetamine 15,000
(MDA)
3,4-Methylenediioxy- 3,4-Methylenediioxyamphetamine
>20,000 >10,000
methamphetamine (MDMA) (MDA)
3,4-
3,4-Methylenediioxy-
Methylenediioxyethylamphetamine >100,000 2,000
methamphetamine (MDMA)
(MDEA)
3,4-
Paramethoxyamphetamine (PMA) 1000 Methylenediioxyethylamphetamine 20,000
(MDEA)
Procaine 100,000
Barbiturate-related compounds Conc Morphine-related compounds Conc
Secobarbital 300 Morphine 2,000
Allobarbital 5000 Codeine 2,000
Alphenal 625 Diacetyl Morphin (Heroin) 2,000
Amobarbital 600 Ethylmorphine 600
Aprobarbital 600 Hydromorphone 15,000
Butabarbital 75 Hydrocodone 15,000
Butalbital 3000 Oxymorphon >20,000
Hexobarbital >100,000 Oxycodone >20,000
Pentobarbital 300 Merperidine >100,000
Phenobarbital 300 6-Monoacetylmorphine 5,000
Morphine-3-glucuronid 10,000
Rifampicin >50,000
Thebaine 20,000
Benzodiazepine - related Methadone - related
Conc Conc
compounds compounds
Oxazepam 300 Methadone 300
Alprazolam 500 Methadol 1,000
Bromazepam 1,000 Doxylamine >40,000
Chlordiazepoxide ≥10,000 EDDP >40,000
8

--- Page 9 ---
Benzodiazepine - related
Conc PCP - related compounds Conc
compounds
Clobazam 300 Phencyclidine 25
Clonazepam 8,000 TCP 3000
Clorazepate 2000
Delorazepam 2400
Desalkflurazepam 2500
Diazepam 300 NOR - related compounds Conc
Estazolam 2,000 Nortriptyline 1000
Fentanyl >100,000 Amitriptyline 1000
Flunitrazepam 1,200 Chlorpromazine 3500
Flurazepam >10,000 Clomipramine 10,000
α-Hydroxyalprazolam 100,000 Cyclobenzaprine 1500
Lorazepam 2,000 Desipramine 500
Lormetazepam 1,000 Diphenyldramine 20,000
Medazepam >100,000 Doxepin 1,000
Midazolam >50,000 Imipramine 800
Nitrazepam >50,000 Nordoxepine 1000
Nordiazepam 300 Perphenazine 2,500
Prazepam >100,000 Promazine 200
Temazepam 500 Promethazine 40,000
Triazolam 2,000 Protryptyline 3000
Trimipramine 2500
Cocaine - Related Compounds Conc THC - related compounds Conc
Benzoylecgonine 300 11-nor-∆9-THC-9-COOH 50
Cocaine 1000 11-nor-∆8-THC-9-COOH 50
Ecgonine 40,000 11-hydroxy--∆9-THC 100,000
Ecgonine methyl ester 100,000 ∆8-THC 15,000
∆9-THC 15,000
Cannabinol 20,000
Cannabidiol 100,000
The following unrelated compounds were found not to cross-react when tested spiked
into drug-free urine at concentrations at 100 µg/ml:
Acetaminophen Furosemide
Acetone Guaiacol Glyceryl Ether
Albumin Hemoglobin
Amitriptyline Ibuprofen
Ampicillin Imipramine
Aspartame (+/-)-Isoproterenol
Aspirin Lidocaine
Atropine N-Methyl-Ephedrine
Benzocaine (+)-Naproxen
Bilirubin Oxalic Acid
Caffeine Penicillin-G
Chloroquine Pheniramine
Chlorpheniramine Phenothiazine
9

--- Page 10 ---
Creatine L-Phenylephrine
Dextrorphan tartrate β-Phenylethylamine
4-Dimethylaminoantipyrine Procaine
Dopamine Quinidine
(+/-)-Ephedrine Ranitidine
(-)-Ephedrine Sulindac
Erythromycin Tyramine
Ethanol Vitamin C
The pH of an aliquoted negative urine pool was adjusted to pH 3, pH 5,
pH6.5, pH 7.5, or pH 8.5; three of the four aliquots at each pH were spiked
with a drug to 75%, 125%, and 300% of the cutoff concentration. The spiked,
pH-adjusted urine was tested in duplicate. Altering the pH of the urine sample
did not affect the accuracy of any of the test results.
Four (4) urine samples with specific gravities of 1.00, 1.01, 1.02, and 1.03
were aliquoted into four samples each; one sample remained neat while the
other three aliquots were spiked with each drug to the concentration of 75%,
125%, and 300% of the cutoff respectively. Each sample was tested in
duplicate. Variations in specific gravity did not affect the accuracy of any of
the test results.
f. Assay cut-off:
Analytical performance of the device around the cutoff is described in Section
1.M.d above.
2. Comparison studies:
a. Method comparison with predicate device:
The ACCUSTEP Multi-Strip Drugs of Abuse Cassette and Dipstick Card
were evaluated in comparison to GC/MS and the predicate. Specimens,
including at least 48 negative and 38 positive samples, were obtained from
commercial reference laboratories. All samples were confirmed by GC/MS
but no clinical information was available:
Agreement between Individual ACCUSTEP Tests and GC/MS
Drug Concentration by GC/MS
ACCU 25 % C/O
<25% >125% Agrmnt
STEP Result Neg to to
C/O C/O w/ GC
Drug C/O +125%
Pos 0 0 0 5 41
AMP 98%
Neg 36 12 7 2 0
Pos 0 0 1 3 42
BAR 98%
Neg 35 10 6 1 0
10

[Table 1 on page 10]
						Drug Concentration by GC/MS																	
ACCU
STEP
Drug			Result			Neg			<25%
C/O			25 %
to
C/O			C/O
to
+125%			>125%
C/O			Agrmnt
w/ GC		
AMP			Pos			0			0			0			5			41			98%		
			Neg			36			12			7			2			0					
																							
BAR			Pos			0			0			1			3			42			98%		
			Neg			35			10			6			1			0					
																							

--- Page 11 ---
Drug Concentration by GC/MS
ACCU 25 % C/O
<25% >125% Agrmnt
STEP Result Neg to to
C/O C/O w/ GC
Drug C/O +125%
Pos 0 3 1 5 36
BZO 94%
Neg 35 12 5 2 0
Pos 0 0 1 4 51
COC 98%
Neg 35 12 6 1 0
Pos 0 0 0 4 45
MTD 98%
Neg 35 11 8 2 0
Pos 0 0 0 4 57
MET 98%
Neg 35 9 8 2 0
Pos 0 0 1 7 33
MOR 98%
Neg 35 21 7 1 0
Pos 0 0 0 5 40
PCP 99%
Neg 35 11 2 1 0
Pos 0 0 0 6 29
NOR 97%
Neg 35 15 7 3 0
Pos 0 0 1 7 53
THC 98%
Neg 35 10 14 2 0
b. Matrix comparison:
Not applicable; these devices are for use with urine only.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
11

[Table 1 on page 11]
						Drug Concentration by GC/MS																	
ACCU
STEP
Drug			Result			Neg			<25%
C/O			25 %
to
C/O			C/O
to
+125%			>125%
C/O			Agrmnt
w/ GC		
BZO			Pos			0			3			1			5			36			94%		
			Neg			35			12			5			2			0					
																							
COC			Pos			0			0			1			4			51			98%		
			Neg			35			12			6			1			0					
																							
MTD			Pos			0			0			0			4			45			98%		
			Neg			35			11			8			2			0					
																							
MET			Pos			0			0			0			4			57			98%		
			Neg			35			9			8			2			0					
																							
MOR			Pos			0			0			1			7			33			98%		
			Neg			35			21			7			1			0					
																							
PCP			Pos			0			0			0			5			40			99%		
			Neg			35			11			2			1			0					
																							
NOR			Pos			0			0			0			6			29			97%		
			Neg			35			15			7			3			0					
																							
THC			Pos			0			0			1			7			53			98%		
			Neg			35			10			14			2			0					

--- Page 12 ---
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
12